Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
+$0.07 today
- Market cap
- $273.18M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
Volume 1.99M
Average 2.06M
EDIT Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Editas Medicine, Inc.NASDAQ: EDIT
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $2.83M fell 39.2% year over year, behind the +8.0% change in trailing-twelve-month revenue. Sequentially, it fell 88.6% from the prior quarter. Over 3 fiscal years it compounded at +27.1% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 8 analysts of $31.98M (-21.1%) for the fiscal year ending Dec 2026, a slowdown from the +25.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.83M-88.6% QoQ
- Last fiscal yearDec 2025
- $40.52M+25.4% YoY
- LTMMar 2026
- $38.69M+8.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -39.2% | -20.4% | +18.8 pp |
| 1 year | +25.4% | -21.1% | -46.5 pp |
| 3-year CAGR | +27.1% | -27.9% | -55.1 pp |
| 5-year CAGR | -13.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 40.52M USD
- Year-over-year change
- +25.4%
- 4-year CAGR
- +12.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 40.52M | +25.4% |
| FY2024 | 2024-12-31 | 32.31M | -58.6% |
| FY2023 | 2023-12-31 | 78.12M | +296.3% |
| FY2022 | 2022-12-31 | 19.71M | -22.8% |
| FY2021 | 2021-12-31 | 25.54M | — |
Revenue vs competitors
How EDIT compares with its peers on the latest reported figures
- EDIT's LTM Mar 2026 revenue of $38.69M is the 4th highest of the 9 companies compared; the peer median is $18.19M.
- Its year-over-year change of +8.0% is the 4th highest of 7, against a peer median of +8.9%.
- Over three fiscal years its annual growth of +27.1% compares with a peer median of +10.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $156.04M | +158.9% | +31.9% | |
| LTM Mar 2026 | $66.09M | +45.0% | +9.1% | |
| LTM Mar 2026 | $45.07M | -11.9% | +10.9% | |
| LTM Mar 2026 | $38.69M | +8.0% | +27.1% | |
| LTM Sep 2026 | $25.17M | -33.1% | +100.4% | |
| LTM Mar 2026 | $11.2M | +13.0% | -7.0% | |
| LTM Mar 2026 | $4.03M | +4.9% | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
SCTXScribe Therapeutics Inc. | — | — | — | — |
| Peer median (excluding EDIT) | $18.19M | +8.9% | +10.9% | |
Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 25.54M | 19.71M | 78.12M | 32.31M | 40.52M |
| Cost of Revenue | 5.05M | 6.34M | 6.06M | 199.25M | 0 |
| Gross Profit | 20.49M | 13.38M | 72.06M | (166.93M) | 40.52M |
| Gross Margin | 80.2% | 67.9% | 92.2% | -516.6% | 100.0% |
| Research & Development | 142.51M | 174.96M | 177.65M | 199.25M | 89.95M |
| Selling, General & Admin | 76.18M | 70.7M | 69.65M | 71.99M | 49.9M |
| Operating Expenses | 213.64M | 239.33M | 241.24M | 84.22M | 139.86M |
| Depreciation & Amortization | 5.05M | 6.34M | 6.06M | 5.81M | 5.28M |
| EBITDA | (187.45M) | (214.1M) | (147.16M) | (233.11M) | (148.61M) |
| EBITDA Margin | -733.8% | -1086.1% | -188.4% | -721.4% | -366.8% |
| Operating Income | (193.15M) | (225.95M) | (169.18M) | (251.15M) | (99.34M) |
| Operating Margin | -756.1% | -1146.3% | -216.6% | -777.2% | -245.2% |
| Interest Income | 607K | 5.52M | 17.57M | 14.06M | 8.31M |
| Interest Expense | 0 | 0 | 0 | 0 | 6.17M |
| Other Income / Expenses | 644K | 5.52M | 15.96M | 14.06M | (60.72M) |
| Income Before Tax | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Pre-Tax Margin | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Net Margin | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| EPS (Basic) | (2.85) | (3.21) | (2.02) | (2.88) | (1.80) |
| EPS (Diluted) | (2.85) | (3.21) | (2.02) | (2.88) | (1.80) |
| Weighted Avg Shares | 67.62M | 68.66M | 75.97M | 82.34M | 88.75M |
| Weighted Avg Shares (Diluted) | 67.62M | 68.66M | 75.97M | 82.34M | 88.75M |
Editas Medicine, Inc.
NASDAQ:EDIT
Intrinsic Alpha fair value
Locked
Current Price
$1.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.